Zydus Lifesciences gets USFDA Approval for generic hypertension drug

Zydus Lifesciences on said it has received nod from the US health regulator to market blood pressure lowering drug Bisoprolol Fumarate and Hydrochlorothiazide tablets in the American market. The company has received approval from the US Food and Drug Administration (USFDA) to market the generic medication in multiple strengths, the Ahmedabad-based drug maker said in a statement. Bisoprolol Fumarate and hydrochlorothiazide combination is shown to treat high blood pressure (hypertension). The drug will be produced at the company's formulation manufacturing facility at Ahmedabad SEZ, the firm said.

As per September 2022 data, Bisoprolol Fumarate and Hydrochlorothiazide tablets had annual sales of USD 27.1 million in the United States.